MDXG Q4 2022 Earnings — MiMedx Group, Inc. Revenue & Financial Results | Market Cap Arena

MDXGMiMedx Group, Inc.

$684M

Q4 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$74M+10.3% YoY

Gross Profit

$60M80.7% margin

Operating Income

$1M1.4% margin

Net Income

-$415,000-0.6% margin

EPS (Diluted)

$-0.00

QoQ Revenue Growth

+9.9%

Cash Flow

Operating Cash Flow

-$6M

Free Cash Flow

-$7M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$171M

Total Liabilities

$97M

Stockholders' Equity

$75M

Cash & Equivalents

$66M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$74M	$67M	+10.3%
Gross Profit	$60M	$57M	+5.9%
Operating Income	$1M	$3M	-67.7%
Net Income	-$415,000	$2M	-118.7%

Revenue Segments

Advanced Wound Care, Tissue And Other

$68M92%

Advanced Wound Care, Umbilical Cord-Derived

$6M8%

Product and Service, Other

$29,0000%